Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study.

@inproceedings{Dizon2015ResultsOA,
  title={Results of a phase I pharmacokinetic study of intraperitoneal bortezomib (B) and carboplatin (C) in patients with persistent or recurrent ovarian cancer (OC): An NRG/Gynecologic Oncology Group study.},
  author={Don S Dizon and William E. Brady and Heather A. Lankes and Danielle A. Jandial and Stephen B. Howell and Russell Schilder and Jan H Beumer and Susan M. Christner and Sandra Strychor and Matthew A. Powell and Andrea R. Hagemann and Kathleen N. Moore and Joan L. Walker and Paul A. Disilvestro and Paula Marie Fracasso and Nrg Oncology},
  year={2015}
}
5515 Background: Intraperitoneal therapy (IP) has been shown to improve survival outcomes for women with optimally cytoreduced, newly diagnosed, advanced OC, but whether IP has a role for recurrent... 

Topics from this paper.